OliX Pharmaceuticals Inc. announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics. The Company is developing the treatment for androgenetic alopecia based on cell-penetrating asymmetric siRNA (cp-asiRNA) platform technology. OLX104C reduces the expression of androgen receptor (AR), one of the key factors that cause androgenetic alopecia, which results in the suppression of the hair cycle transition from anagen to telogen phase.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14,820 KRW | -2.37% | +0.47% | +1.65% |
1st Jan change | Capi. | |
---|---|---|
+1.65% | 181M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- A226950 Stock
- News OliX Pharmaceuticals, Inc
- Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss